Amro Albanna (00:07): Okay, we're just gonna, we're just gonna go ahead and wait a few seconds, as we always do as attendees are joining. I do have Friedrich here, and I'm just looking at the attendee list. Let's see. I

Amro Albanna (00:07):

Okay, we're just gonna, we're just gonna go ahead and wait a few seconds,

as we always do as attendees are joining. I do have Friedrich here, and I'm just looking at the attendee list. Let's see. I see a few

people from our team. Okay. I am just waiting a couple more seconds. Very good. Welcome everybody. Thanks for joining us. Today I do have

Friedrich and Saundra joining us. And I'm sure, you know, almost everyone knows Friedrich and Saundra, but with that, maybe we should

still do a quick introduction. So Saundra, maybe you can go ahead and just do a quick intro.

Saundra Pelletier (00:56):

Okay, great. Thank you. I'm Saundra Pelletier, the CEO of Evofem Biosciences.

Our focus is on women's health, and currently we have two FDA approved assets that are both generating revenue, but we are really focused

on innovations that really deliver unmet needs for women.

Amro Albanna (01:16):

Wonderful. Thanks, Saundra. I know you and I spoke a couple weeks ago

already. I appreciate you joining. I know you're busy. Everybody's busy right now, but I thought this would be a really good opportunity

for us to continue to give these weekly updates, our team, our stakeholders, our vendors. And today I will focus on the theme we discussed

right before the call. But obviously before I go there, Friedrich, maybe you can do a quick intro as well.

Friedrich Kapp (01:40):

Yeah. Thank you very much. Amro. I'm Friedrich Kapp and I'm responsible

for the development of ADI-100, which is our first drug in the autoimmune space. And our goal is to get ready for clinical trials by the

end of the year. So we are really very far advanced and we, we'll probably have a chance to talk about this more during this call.

Amro Albanna (02:06):

Great. And I'm glad you said end of the year, because that is exactly

gonna be our focus, and we'll certainly talk about, again, the challenge that we must address collectively, frankly, as Aditxt, as Adimune

as Pearsanta, and as Evofem. And with that, actually Chris could not make it. We did announce that Chris will join. Chris is at the airport,

and we decided it's probably not a good idea for him to be, you know, to join while he's on the road. And Chris, we're probably gonna

do one with him either next week or the following week. So with that, again, I know, Saundra, I know you're, you're, you're really busy,

Friedrich, I know you're super busy. We're trying to keep the company moving forward. So I thought today, you know, as we do these weekly

updates, it's, it's important for us to make sure that whoever joins understand what it is that we are looking to do, and frankly, the

things that we're looking to address.

So, you know, Aditxt, with that background, Aditxt currently has two

programs. We have the Adimune program, which is focused on addressing autoimmunity, and we'll talk about that a little bit more. And then

we have Pearsanta, which is focused on addressing early disease detection, starting with endometriosis and prostate cancer. And then Evofem,

which is a pending transaction. We're still pushing to try to close it by end of September dealing with women's health. So that's a little

bit of the kind of the background and the focus today. Look, we must keep our eyes focused on what we need to accomplish by end of the

year, what that would mean for Adimune, what that would mean for Pearsanta, what that would mean for Evofem, and what that would mean

for Aditxt as a whole, right? So we can talk about that.

But reality is from here until then, the key ingredient that we must

address is capital. Now, I know every single company, every single early stage, every single startup will always talk about capital. But

let me be very clear, we're all experienced, seasoned entrepreneurs, I personally do not believe money is the solution for all, right?

We understand that companies raise money and lose money and go out of business, but I believe we have positioned Aditxt and each of its

programs, including the pending transaction of Evofem, to the point where capital can be very meaningful, can be very transformational.

So today I wanna really focus on these two aspects. One, what would Adimune achieve from now until end of the year? And why would that

be transformational for Adimune? I want to do the same, and I'll speak on behalf of Chris, what that would mean for Pearsanta. And then

of course, Saundra, you can talk about Evofem, what that would mean for you by end of the year where you see Evofem, you know, by end

of this year. And then we'll, we'll talk very frankly about capital, capital, capital, capital, right? And some of the challenges, whether

it's payroll vendors, lenders, all that needs to be done. So Friedrich, maybe we'll start with you, kinda, at a very high level, what

is it that you would like to accomplish by end of the year for Adimune? In terms of major milestones?

Friedrich Kapp (05:26):

I mean, the key, key milestone for us at this point, of course, is

to put everything that we have generated together in a document or documents for the health authority, then send it to the health authority

and ask for approval to go into application in patients. And, and I mean, we have everything that we need. We have toxicology. We show

that the gene the genes, the plasmids don't are not detected in the organs. We don't have antibody formation. So the safety aspects are

there. And the latest, of course is the these wonderful data that were generated at Mayo where we have shown, or they have shown that

with our ADI100 drug ex-vivo, so not for with cells from patients, then with our drug, the, the aggressive T-cells can be eliminated.

And that is of course, as close as you can get to data from patients at this point. So very encouraging. And I think the health authorities

will like that aspect particularly because it also has to do with safety, but also with efficacy. Efficacy. So both elements are there.

Uh, and so it's a matter of putting things together. You know, we are so far advanced.

Amro Albanna (07:01):

So, Friedrich, you know, ADI platform, we've been on, on a path a long

path to get it to this point by end of this year. Our goal is to, to to, to be able in a position to actually submit or have submitted

to the FDA and PEI in Germany for type one diabetes, psoriasis, and here in the US would be stiff person syndrome. And those are, you

know, obviously the initial indications. But our goal is to, you know, hopefully we can show not only safety, but potentially efficacy

and using these indications as proof of concept for Adimune. So by end of the year, do you at, you know, obviously our goal here is to

be to, to, to file in Q4 with these authorities. Is that, is that fair to say?

Friedrich Kapp (07:48):

Yeah, Absolutely. And you see, it's, it's not a normal drug. It's not

a normal drug that we are dealing with. It's something totally different. It's it's fundamentally changing the approach that it has been

going on for treating autoimmune disease because we are restoring immune tolerance. And that is unique essentially, because I don't know

of any drug that has that can do that. And therefore I think it's very exciting for us to be at this point where we can, we're so close

to go into patients and see that. The point is, and, and I mentioned that before, we are eliminating the cause, you know, of the disease,

be it especially easily to understand in type one diabetes. And when, you know, when you eliminate the cause of the disease, then the

disease is gone. So it's, you know, and the uniqueness of type one diabetes again is that it is a one medication disease right now insulin

and to replace insulin essentially is of course also a very attractive aspect of what we are doing. Because we're opening this market.

Amro Albanna (09:07):

You're, you're, you're, look, we've, we've, we've been at it for years,

Friedrich, and your excitement has never wavered truly, and your belief has never wavered. And I can tell you, and people that are, that

don't know you of course are, you know Friedrich is not an excitable person and, you know, his, his confidence. Look, we obviously cannot,

cannot predict efficacy in biology. We cannot but what we're focused on right now is the preclinical data that we've had so far certainly

looks pretty encouraging. And that's why by end of this year, transitioning ADI and Adimune to human trials, now we're not sure if we

can begin human trials, but at least, at least submit to the regulatory and possibly, possibly receive approval if we do. But certainly

that would position Adimune in 2026 for human trials, assuming we get the approvals that would become a big year for Adimune. So with

that, Saundra, maybe I can do the same with you. Okay. We, we, we know Evofem. We know Phexxi, we know Solosec. And again, I repeat myself

cause I just never know who else, you know, who, you know, who else is on the line and who, who heard you and who hasn't heard you before.

So just tell us, you know, aside from the capital, where do you see Evofem by end of the year, truly, where do you see Evofem as a company

focused on women's health and innovations?

Saundra Pelletier (10:38):

Well, I think it's a, I think the question is tricky because the answer

really does depend on capital. We right now have two assets that generate revenue. We brought in $20 million of net revenue last year.

We only just launched. Solosec at the end of the year, it was on a $20 million trajectory when the product was stopped being promoted.

So we have Phexxi and Solosec, the same call point. There's absolute efficiencies with our sales team. We have had no attrition in our

company based on everything that's happened to us. You would think we would, but we have had no investment in these brands in two and

a half years. We have payables that have to be addressed in order for us to manage our business. Our payables are, we have to buy raw

material supply. We have to manufacture this drug. We have to package this drug.

We have to distribute this drug. We have to pay FDA fees because we

are a prescription product. These aren't things like getting fancy lattes. These are things that are heavy and serious, and many companies

like ours have went out of business, but we had the grit and the resilience to go through painful, painful things. I talk to vendors every

day. I, I've become a hustler. I'm a professional hustler. I say truthful things. I beg, I, people are on payment plans. We know this

business is worth it. We do, we know the market opportunity is real. It's not fantasy. We know that there are windows of opportunity,

like with things like GLP-1s right now on social media. There were three articles that came up this morning of a pervasive epidemic of

women getting pregnant on GLP-1s. The only only birth control that has no systemic activity that will not interact with other products

that are women are on is Phexxi, period.